Novo Nordisk reported DKK34.72B in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Bausch Health Companies USD 837M 94M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Novo Nordisk DKK 34.72B 2.57B Mar/2026
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pacira USD 40.24M 1.53M Mar/2026
Sanofi EUR 3.31B 3.65B Mar/2026
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026